AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19
March 23, 2021 | 11:10
The AstraZeneca US Phase III trial of AZD1222 demonstrated 79 per cent vaccine efficacy at preventing symptomatic COVID-19 and 100 per cent efficacy at preventing severe disease and hospitalisation.
COVID-19 vaccine AstraZeneca conditionally authorised for emergency use in Vietnam
February 02, 2021 | 10:14
AstraZeneca’s COVID-19 vaccine was granted conditional authorisation to help address the urgent need for the prevention and control of COVID-19 in Vietnam.
Mobile Version